Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan Long-term Extension in Inoperable CTEPH
NCT00319111Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jan 2006
- Primary completion
- Feb 2009
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
01
Overview
Phase 3, open-label, single-arm trial of bosentan in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Change From Baseline in 6-minute Walk Distance up to 3.3 years, Change From Baseline in Borg Dyspnea Index up to 3.3 years and 2 more. Started Jan 2006; status: completed.
02
Drugs
bosentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT00319111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00319111.